Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results
August 08, 2023 22:17 ET
|
Belite Bio, Inc
Completed enrollment in pivotal Phase 3 “DRAGON” trial for Tinlarebant in adolescent Stargardt disease (“STGD1”) with 100 subjects enrolled across 11 countries worldwideFirst subject dosed with...
Belite Bio to Host Webcast on August 9, 2023 to Discuss Second Quarter 2023 Financial Results
August 04, 2023 08:00 ET
|
Belite Bio, Inc
SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company focused on advancing novel...
Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GA
July 27, 2023 17:00 ET
|
Belite Bio, Inc
Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended to slow disease progression in subjects with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry...
Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease
July 24, 2023 06:04 ET
|
Belite Bio, Inc
Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended to slow disease progression in patients with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry...
Belite Bio Announces Pricing of $30 Million Underwritten Public Offering of American Depositary Shares and Warrants
May 30, 2023 20:49 ET
|
Belite Bio, Inc
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical stage biopharmaceutical drug development company focused on advancing novel...
Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares and Warrants
May 30, 2023 16:01 ET
|
Belite Bio, Inc
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical stage biopharmaceutical drug development company focused on advancing novel...
Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results
May 10, 2023 19:58 ET
|
Belite Bio, Inc
In 18-month interim data from ongoing 2-year, Phase 2 Stargardt disease (“STGD1”) trial (“LBS-008-CT02”), we continued to observe that oral Tinlarebant is safe and well tolerated in adolescent STGD1...
Belite Bio to Host Webcast on May 11, 2023 to Discuss First Quarter 2023 Financial Results
May 10, 2023 15:33 ET
|
Belite Bio, Inc
SAN DIEGO, May 10, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal...
Belite Bio to Host Key Opinion Leader Webinar Discussing Progression of Childhood-onset STGD1 and Relevance of the Tinlarebant 18-month Phase 2 Data
May 04, 2023 11:09 ET
|
Belite Bio, Inc
The webinar will take place on Wednesday, May 10, 2023 at 1:00 PM ET SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical stage biopharmaceutical drug development...
Belite Bio Presented 18-Month Interim Data from a 24-Month Phase 2 Study of Tinlarebant in Adolescent Stargardt Disease at the 2023 ARVO Meeting
April 25, 2023 16:30 ET
|
Belite Bio, Inc
Tinlarebant (aka LBS-008) continues to be safe and well tolerated in adolescent Stargardt Disease (STGD1) subjects at the 18-month time pointA continued trend of slowing expansion of autofluorescence...